The impact of GGH -401C %26gt; T polymorphism on cisplatin-based chemoradiotherapy response and survival in cervical cancer

作者：Silva Ines Hilario; Nogueira Silva Cristina; Figueiredo Tiago; Lombo Liliana; Faustino Ilda; Catarino Raquel; Nogueira Augusto; Pereira Deolinda; Medeiros Rui^*

来源：Gene, 2013, 512(2): 247-250.

DOI：10.1016/j.gene.2012.10.038

• Cervical cancer
• GGH
• olymorphism
• Cisplatin response

Aims: Cervical cancer is the third most frequent cancer in women worldwide, mostly treated with cisplatin-based chemoradiotherapy. Since it is known that folate metabolism might interfere with cisplatin effectiveness, we intended to study the influence of the Gamma Glutamyl Hydrolase -401C %26gt; T polymorphism in treatment response in cervical cancer. %26lt;br%26gt;Methods: We retrospectively reviewed the clinical data of 167 patients with bulky cervical cancer submitted to cisplatin-based chemoradiotherapy. The genotypes of GGH -401C %26gt; T SNP were determined by real-time PCR and statistical analysis was performed by chi(2) test and survival analysis. %26lt;br%26gt;Results: The genotypes of GGH-401C %26gt; T were significantly associated with the response to platinum-based chemoradiotherapy. Treatment response was higher in patients carrying the CC genotype, who presented a significant increased chance of treatment response (survival time in months/genotype: 91 for CC Vs 72 for CT/TT; p = 0.035, log rank test). A Cox regression analysis accordingly showed that the presence of the T allele was significantly linked to a worse treatment response (HR = 3.036; CI 95% 1.032-8.934, p = 0.044). %26lt;br%26gt;Conclusions: The results of our study suggested the potential interest of GGH -401C %26gt; T as a predictive factor of the outcome of cervical carcinoma treated with cisplatin-based chemoradiotherapy.

• 出版日期2013-1-10